Lupin eyes double-digit growth in second half of FY25, focuses on strengthening US business
CEO Vinita Gupta stated that Lupin expects to maintain a quarterly range of $220-230 million for its US business, driven by its existing product lineup, a strong respiratory franchise, and the ramp-up of Mirabegron.

What's Your Reaction?






